Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.34 Insider Own5.40% Shs Outstand53.27M Perf Week-4.10%
Market Cap80.97M Forward P/E- EPS next Y-1.22 Insider Trans0.00% Shs Float50.39M Perf Month9.35%
Income-55.09M PEG- EPS next Q-0.19 Inst Own55.41% Short Float0.84% Perf Quarter-7.32%
Sales0.00M P/S- EPS this Y43.17% Inst Trans4.30% Short Ratio2.69 Perf Half Y8.57%
Book/sh0.75 P/B2.03 EPS next Y-54.75% ROA-53.21% Short Interest0.42M Perf Year-53.80%
Cash/sh1.68 P/C0.90 EPS next 5Y- ROE-117.39% 52W Range1.12 - 3.62 Perf YTD-8.98%
Dividend Est.- P/FCF- EPS past 5Y-7.22% ROI-59.96% 52W High-58.01% Beta1.64
Dividend TTM- Quick Ratio22.75 Sales past 5Y-29.33% Gross Margin40.20% 52W Low35.71% ATR (14)0.10
Dividend Ex-Date- Current Ratio22.75 EPS Y/Y TTM4.00% Oper. Margin0.00% RSI (14)54.13 Volatility7.56% 7.29%
Employees47 Debt/Eq1.32 Sales Y/Y TTM-100.00% Profit Margin- Recom1.50 Target Price10.25
Option/ShortYes / Yes LT Debt/Eq1.30 EPS Q/Q40.84% Payout- Rel Volume0.69 Prev Close1.48
Sales Surprise- EPS Surprise19.23% Sales Q/Q-100.00% EarningsMay 13 BMO Avg Volume157.22K Price1.52
SMA206.66% SMA500.08% SMA200-21.81% Trades Volume109,188 Change2.70%
Date Action Analyst Rating Change Price Target Change
Jun-20-23Downgrade Jefferies Buy → Hold $8 → $4
Apr-22-22Upgrade Piper Sandler Neutral → Overweight $8 → $10
Mar-05-21Initiated H.C. Wainwright Buy $20
Jul-29-20Upgrade Oppenheimer Perform → Outperform $18
Jul-24-20Upgrade Jefferies Hold → Buy
Mar-25-20Downgrade Jefferies Buy → Hold $28 → $3
Mar-24-20Downgrade Piper Sandler Overweight → Neutral $26.50 → $3
Mar-24-20Downgrade Oppenheimer Outperform → Perform
Jun-04-19Initiated Oppenheimer Outperform $32
Jun-03-19Initiated Piper Jaffray Overweight $26.50
Jul-15-24 08:00AM
Jun-12-24 08:00AM
May-31-24 08:00AM
May-29-24 07:00AM
May-22-24 08:00AM
12:00PM Loading…
May-16-24 12:00PM
May-13-24 01:53PM
May-02-24 08:00AM
Apr-17-24 08:00AM
Apr-08-24 11:36AM
Apr-03-24 08:00AM
Apr-01-24 08:00AM
Mar-28-24 07:00AM
01:53PM Loading…
Mar-21-24 01:53PM
Feb-29-24 04:01PM
Feb-28-24 04:37PM
Feb-26-24 07:00AM
Jan-18-24 01:23PM
Jan-16-24 09:35AM
Dec-27-23 11:11AM
Dec-26-23 10:55AM
Nov-21-23 07:00AM
Nov-13-23 07:02AM
Nov-11-23 10:00AM
07:00AM Loading…
Nov-07-23 07:00AM
Oct-24-23 07:00AM
Oct-06-23 07:00AM
Sep-27-23 07:00AM
Sep-05-23 07:00AM
Aug-10-23 07:56AM
Aug-08-23 09:55AM
Jun-20-23 07:00AM
Jun-10-23 09:40AM
Jun-01-23 07:00AM
May-22-23 07:00AM
May-11-23 07:31AM
May-08-23 07:00AM
May-01-23 06:02AM
Apr-21-23 09:23AM
Apr-12-23 07:00AM
Mar-31-23 10:39AM
Mar-29-23 09:17AM
Mar-28-23 07:00AM
Mar-06-23 07:00AM
Feb-28-23 07:00AM
Jan-16-23 12:00PM
Jan-01-23 08:33AM
Dec-13-22 09:35AM
Dec-02-22 02:11PM
Nov-29-22 07:00AM
Nov-22-22 07:00AM
Nov-12-22 07:47AM
Nov-10-22 07:21AM
Nov-07-22 12:13PM
Oct-25-22 07:00AM
Oct-22-22 08:21AM
Oct-20-22 09:35AM
Oct-18-22 06:30PM
Oct-17-22 09:14AM
Sep-11-22 03:13PM
Sep-06-22 07:00AM
Aug-10-22 04:15PM
Jul-24-22 10:28AM
Jun-02-22 07:00AM
May-27-22 05:03PM
May-23-22 06:23AM
May-17-22 07:00AM
May-12-22 07:15AM
Apr-30-22 09:00AM
Apr-15-22 04:41PM
Apr-14-22 07:00AM
Mar-24-22 07:20AM
Mar-01-22 07:00AM
Feb-16-22 07:00AM
Feb-14-22 01:03PM
Jan-04-22 07:00AM
Dec-14-21 07:56AM
Nov-15-21 07:00AM
Nov-12-21 07:20AM
Nov-11-21 07:00AM
Oct-15-21 09:31AM
Sep-22-21 07:00AM
Sep-07-21 07:00AM
Aug-16-21 10:58AM
Aug-11-21 04:18PM
Aug-03-21 09:01AM
May-26-21 07:00AM
May-17-21 01:22PM
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.